Reviewing Fibrocell Science (FCSC) and Zynerba Pharmaceuticals (ZYNE)
Fibrocell Science (NASDAQ: FCSC) and Zynerba Pharmaceuticals (NASDAQ:ZYNE) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, earnings, dividends, profitabiliy, valuation and risk.
Earnings and Valuation
This table compares Fibrocell Science and Zynerba Pharmaceuticals’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Fibrocell Science||$338,999.00||124.41||-$19.14 million||($1.53)||-1.88|
|Zynerba Pharmaceuticals||N/A||N/A||-$26.59 million||($2.68)||-6.20|
Fibrocell Science has higher revenue and earnings than Zynerba Pharmaceuticals. Zynerba Pharmaceuticals is trading at a lower price-to-earnings ratio than Fibrocell Science, indicating that it is currently the more affordable of the two stocks.
This table compares Fibrocell Science and Zynerba Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Volatility and Risk
Fibrocell Science has a beta of 0.34, suggesting that its stock price is 66% less volatile than the S&P 500. Comparatively, Zynerba Pharmaceuticals has a beta of 5.17, suggesting that its stock price is 417% more volatile than the S&P 500.
This is a breakdown of recent recommendations and price targets for Fibrocell Science and Zynerba Pharmaceuticals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Fibrocell Science currently has a consensus target price of $5.30, indicating a potential upside of 84.67%. Zynerba Pharmaceuticals has a consensus target price of $32.25, indicating a potential upside of 94.16%. Given Zynerba Pharmaceuticals’ higher possible upside, analysts clearly believe Zynerba Pharmaceuticals is more favorable than Fibrocell Science.
Institutional and Insider Ownership
55.0% of Fibrocell Science shares are held by institutional investors. Comparatively, 30.4% of Zynerba Pharmaceuticals shares are held by institutional investors. 2.1% of Fibrocell Science shares are held by insiders. Comparatively, 10.0% of Zynerba Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Zynerba Pharmaceuticals beats Fibrocell Science on 7 of the 11 factors compared between the two stocks.
About Fibrocell Science
Fibrocell Science, Inc. is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related. It is investigating the indication in a Phase II clinical trial. Its gene-therapy product candidate, FCX-007, is in pre-clinical development for the treatment of recessive dystrophic epidermolysis bullosa. Its gene-therapy product candidate, FCX-013, is in pre-clinical development for the treatment of linear scleroderma. Its product, LAVIV (azficel-T), is indicated for the improvement of the appearance of moderate to severe nasolabial fold wrinkles in adults. A third gene-therapy program is focused on the treatment of arthritis. Its product, LAVIV (azficel-T), is focused on improving the appearance of nasolabial fold wrinkles in adults.
About Zynerba Pharmaceuticals
Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is engaged in developing and commercializing transdermal synthetic cannabinoid treatments for patients with high unmet needs. Its development pipeline includes two product candidates: ZYN002 and ZYN001. ZYN002 is a synthetic cannabidiol (CBD), which is a non-psychoactive cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system. ZYN002 is in Phase II clinical development in patients with refractory epilepsy, in patients with osteoarthritis of the knee, as well as in patients with Fragile X syndrome. ZYN001 is a pro-drug of tetrahydrocannabinol (THC) that enables transdermal delivery through the skin and into the circulatory system through a patch. ZYN001 is targeting two pain indications, fibromyalgia and peripheral neuropathic pain.
Receive News & Ratings for Fibrocell Science Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fibrocell Science Inc and related companies with MarketBeat.com's FREE daily email newsletter.